Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.

Gro TunheimGunnar Øyvind Isaksson RøAdity ChopraAudun AaseAnne-Marte Bakken KranJohn Torgils VaageFridtjof Lund-JohansenOlav Hungnes

Published in: Influenza and other respiratory viruses (2022)

The high overall SARS-CoV-2 seroprevalence estimates are in line with Norwegian registry data. Vaccination, not infection, contributed the most to the high seroprevalence in August 2021. Lack of antibodies against nucleocapsid should not automatically be interpreted as absence of previous infection as this could lead to underestimation of COVID-19 cases in seroprevalence studies.

Keyphrases

sars cov
respiratory syndrome coronavirus
coronavirus disease
risk factors
machine learning